Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Jun 30, 2021 • 7:36 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Earlier this month, Atai Life Sciences N.V. (Nasdaq: ATAI) commenced trading on the Nasdaq and we have been closely following the trend since listing. The company is a high-profile psychedelic therapy business and has received investments from several big money investors. 

Although Atai is considered to be one of the best ways to play the psychedelic therapy sector, the recent trend has been to the downside. Atai has come well off its mid-June highs but is still valued at more than $2.5 billion (based on the market capitalization on June 24, 2021).  

In 2020, Atai reported a net loss of $169.8 million on no revenue. Although this amount is significantly higher than the $24.1 million net loss that was reported in 2019, biotech companies tend to not generate revenue for years. Once a biotech company brings a therapy to market, the business starts to generate revenue and we expect ATAI to follow a similar path. 

Atai describes itself as a drug development platform that was formed to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions. Atai has partnered with 14 companies that are focused on drug development and other technologies. As part of the operating structure, the company receives a majority ownership stake from the therapies and technologies that it partners with. In return, the company helps its partners with raising capital, working with the regulators, and conducting clinical trials. 

Atai bounced higher after it commenced trading and found resistance below the $23 level. This comes after the IPO was priced between $15 to $17 and we continue to closely follow price movements. As of June 24th, Atai was trading above this range and we will monitor the trend from here.

If you are interested in learning more about ATAI Life Sciences, please send an email to support@technical420.com with the subject “ATAI Life Sciences” to be added to our distribution list. 

For the fastest access to data on ATAI Life Sciences, sign up for our free newsletter!

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.